Table 1.
Demographic and baseline clinical characteristics for the 379 patients.
| Mean (SD) | Number (%) | ||
|---|---|---|---|
| Age at inclusion, years | 57 (15) | ||
| Disease duration, months | 6.3 (3.2) | ||
| Women | 241 (64) | ||
| Anti CCP positive | 210 (61) | ||
| RF positive | 221 (65) | ||
| DAS28 | 5.07 (1.2) | ||
| ESR | 38 (26) | ||
| CRP, mg/L | 37 (38) | ||
| HAQ, 0-3 | 0.97 (0.61) | ||
| Total Sharp score (SHS) | 4.0 (8.2) | ||
| Erosion score (ES) | 1.7 (3.8) | ||
| Joint space narrowing score (JSN) | 2.3 (5.2) | ||
| Prednisolone | 1876 (50) | ||
| DMARDS | None | 77 (20) | |
| Methotrexate | 155 (41) | ||
| Sulfasalazine | 102 (27) | ||
| Other DMARD | 44 (12) | ||
| Combination | 1 (0) | ||
| Biologics | 0 (0) | ||
Anti-CCP, antibodies against cyclic citrullinated peptides; CRP, C-reactive protein; DAS28, Disease Activity Score calculated on 28 joints; DMARDS, disease modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; N, number; RF, rheumatoid factor; SD, standard deviation.